Patient disposition and discontinuations
| . | Treated patients, n (%) . | |
|---|---|---|
| . | Dasatinib 100 mg qd, n = 258 . | Imatinib 400 mg qd, n = 258 . |
| Still on treatment | 183 (71) | 179 (69) |
| Discontinued | 75 (29) | 79 (31) |
| Progression* | 17 (7) | 18 (7) |
| Treatment failure† | 8 (3) | 12 (5) |
| Adverse event | 27 (10) | 16 (6) |
| Nonhematologic | 20 (8) | 12 (5) |
| Hematologic | 7 (3) | 4 (2) |
| Unrelated adverse event | 6 (2) | 2 (<1) |
| Death‡ | 4 (2) | 1 (<1) |
| Poor/nonadherence§ | 0 (0) | 4 (2) |
| Other|| | 13 (5) | 26 (10) |
| . | Treated patients, n (%) . | |
|---|---|---|
| . | Dasatinib 100 mg qd, n = 258 . | Imatinib 400 mg qd, n = 258 . |
| Still on treatment | 183 (71) | 179 (69) |
| Discontinued | 75 (29) | 79 (31) |
| Progression* | 17 (7) | 18 (7) |
| Treatment failure† | 8 (3) | 12 (5) |
| Adverse event | 27 (10) | 16 (6) |
| Nonhematologic | 20 (8) | 12 (5) |
| Hematologic | 7 (3) | 4 (2) |
| Unrelated adverse event | 6 (2) | 2 (<1) |
| Death‡ | 4 (2) | 1 (<1) |
| Poor/nonadherence§ | 0 (0) | 4 (2) |
| Other|| | 13 (5) | 26 (10) |
Progression was defined as doubling of white blood cell count to >20 × 109/L, loss of CHR, increase in Ph-positive BM metaphases to ≥30% from nadir, transformation to accelerated phase/blast phase, or death from any cause.
Failure was defined as no hematologic response by 3 months, no CHR or cytogenetic response by 6 months, no PCyR by 12 months, or no CCyR by 18 months.
Patient discontinuations because of death (shown in table) represent a subset of total deaths (17 in dasatinib-treated patients and 20 in imatinib-treated patients at time of database lock).
As reported by investigators.
Includes consent withdrawal, loss to follow-up, pregnancy, patient request, and other reasons.